急性间质性肾炎治疗的系统综述
该系统综述评估急性间质性肾炎(AIN)药物治疗的疗效与安全性,检索多个数据库后纳入23篇文章(3项随机对照试验、4项病例系列、16项回顾性队列研究)。对3项研究的Meta分析显示泼尼松龙改善肾脏结局,但各研究在剂量、疗程和起始时机上存在显著差异,皮质类固醇相关不良事件可能被漏报。
要点
- 对3项研究的Meta分析显示泼尼松龙改善肾脏结局。
- 各研究在剂量、疗程和起始时机上存在显著差异。
- 皮质类固醇相关不良事件可能被漏报。
核心结论
- 支持使用皮质类固醇治疗AIN的一致性证据尚不够全面。
- 需要就最佳治疗方案达成明确共识。
- 需要高质量随机对照试验以帮助建立循证指南。
研究设计与样本
- 系统综述,检索PubMed、Embase、Cochrane Library等主要数据库,检索时间为2024年6月,已在国际前瞻性系统综述注册平台注册。
- 纳入经组织学诊断的AIN治疗研究,共纳入23篇文章:3项随机对照试验、4项病例系列、16项回顾性队列研究。
- 采用固定效应Meta分析和Meta回归,使用Stata SE 16进行。
主要发现
- 共3597篇文章符合筛选条件。
- 大多数研究中皮质类固醇是主要治疗,1项研究评估了霉酚酸酯(MMF)用于类固醇难治性患者。
- 对3项研究的Meta分析显示泼尼松龙使用改善肾脏结局。
- 各研究在剂量、疗程和起始时机上存在显著差异。
- 皮质类固醇相关不良事件可能被漏报。
临床怎么用
- 原文未据此给出推荐。
局限性
- 各研究在剂量、疗程和起始时机上存在显著差异。
- 皮质类固醇相关不良事件可能被漏报。
- 支持使用皮质类固醇治疗AIN的一致性证据尚不够全面。
- 需要就最佳治疗方案达成明确共识。
- 需要高质量随机对照试验以帮助建立循证指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute interstitial nephritis (AIN) is a common cause of acute kidney injury. It is characterized by tubular inflammation with eosinophils histologically. The mainstay treatment for AIN includes early diagnosis; underlying infection or systemic disease treatment; cessation of the offending agent; and corticosteroid therapy, when indicated. This systematic review aims to evaluate the efficacy and safety of pharmacotherapy treatments for AIN by assessing treatment outcomes and adverse effects. METHODS: PubMed, Embase, Cochrane Library, and other major databases were systematically searched in June 2024 after registration with the International Prospective Register of Systematic Reviews. Manual searches of the references in relevant articles were conducted. Studies focusing on the treatment of AIN cases that were diagnosed histologically were included. A fixed-effects meta-analysis and meta-regression were performed using Stata SE 16. RESULTS: A total of 3597 articles were eligible for screening. Twenty-three articles were included in the systematic review. There were 3 randomized controlled trials, 4 case series, and 16 retrospective cohort studies. Corticosteroids were the primary treatment in most of the studies, with 1 study evaluating the use of mycophenolate mofetil (MMF) in steroid-refractory patients. A meta-analysis of 3 studies showed that prednisolone use improved renal outcomes. There was significant variability across studies in dosing, treatment duration, and timing of initiation. Adverse events associated with corticosteroids were likely underreported. CONCLUSION: Consistent evidence supporting the use of corticosteroids for treating AIN needs to be more comprehensive. There needs to be a clear consensus on the optimal treatment regimen. High-quality randomized controlled trials are required to help establish evidence-based guidelines for treating AIN.
引用
- Yu Y, Biros E, Chang X, et al. A Systematic Review of Treatment for Acute Interstitial Nephritis. Kidney Int Rep. 2025. PMID: 40814598. doi:10.1016/j.ekir.2025.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。